본문 바로가기
HOME> 저널/프로시딩 > 저널/프로시딩 검색상세

저널/프로시딩 상세정보

권호별목차 / 소장처보기

H : 소장처정보

T : 목차정보

The breast journal 61건

  1. [해외논문]   Issue Information  


    The breast journal v.24 no.4 ,pp. 453 - 458 , 2018 , 1075-122x ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  2. [해외논문]   Treatment of HER2‐positive early breast cancer: How to best balance efficacy and toxicity?   SCIE

    Azim, Hamdy A. (The Department of Clinical Oncology, School of Medicine, Cairo University, Cairo, Egypt) , Lasheen, Shaimaa (The Department of Clinical Oncology, School of Medicine, Cairo University, Cairo, Egypt) , Kassem, Loay (The Department of Clinical Oncology, School of Medicine, Cairo University, Cairo, Egypt)
    The breast journal v.24 no.4 ,pp. 459 - 461 , 2018 , 1075-122x ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  3. [해외논문]   Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo‐adjuvant treatment for Her2 positive breast cancer patients and impact of colony‐stimulating factor prophylaxis   SCIE

    Bayo, Juan (Department of Medical Oncology, Complejo Hospitalario de Huelva, Huelva, Spain) , Aviñ (Department of Medical Oncology, Complejo Hospitalario de Huelva, Huelva, Spain) , ó (Department of Medical Oncology, Complejo Hospitalario de Huelva, Huelva, Spain) , , Victoria (Department of Medical Oncology, Complejo Hospitalario de Huelva, Huelva, Spain) , Toscano, Fá , tima , Jimé , nez, Francisco
    The breast journal v.24 no.4 ,pp. 462 - 467 , 2018 , 1075-122x ,

    초록

    Abstract While the docetaxel, carboplatin, and trastuzumab (TCH) regimen is one of the standard treatments in Her2‐positive breast cancer, however, acute toxicities, especially those related to the high rate of neutropenia are consistently reported. Primary : To compare the toxicity of TCH in current clinical practice vs the toxicity observed in the pivotal study, comparing the toxicity in patients that received primary prophylaxis (PP) with colony‐stimulating factors vs those that did not receive PP. Secondary : To describe the demographic and clinical characteristics of the study sample, as well as the adverse effects and survival. The data regarding 95 patients were analyzed. Observed toxicity (hematological and extra‐hematological) was greater compared to the pivotal study, with the exception of neuropathy and neutropenia. Toxicities “ PP ” vs “ no PP ” : Extra‐hematological grade 3‐4 toxicities: Significant reduction was observed in the “ PP ” group vs the “no PP” group referred to fatigue, stomatitis, nausea, and vomiting. Hematological grade 3‐4 toxicities: Lesser neutropenia, leukopenia, and febrile neutropenia were observed in the “PP” group. Complications associated to treatment: No grade 3‐4 cardiac toxicity, leukemia or deaths were recorded. DFS and OS : After a mean follow‐up of 22.9 months, only one bone metastatic relapse was detected (DFS: 98.9%; OS: 100%). The combination TCH is very active and effective as adjuvant and neo‐adjuvant therapy in Her2‐positive breast cancer, and is currently regarded as standard treatment. However, global toxicity as well as hematological toxicity is elevated. The incorporation of PP to TCH significantly reduces hematological toxicity and some of the global toxicity, thus favoring treatment implementation and lessening the clinical complications. We therefore recommend generalization of PP with colony‐stimulating factors in patients receiving TCH.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  4. [해외논문]   Impact of 2013 ASCO/CAP HER2 reporting guidelines in breast cancer: An assessment study from Indian oncology centre that primarily performs HER2 IHC testing with special emphasis on IHC equivocal category   SCIE

    Pasricha, Sunil (Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India) , Gupta, Gurudutt (Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India) , Garg, Ritu (Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India) , Sharma, Anila (Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India) , Gandhi, Jatin S. (Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India) , Durga, Garima (Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India) , Kamboj, Meenakshi (Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute & Research Centre, Del) , Grover, Shrruti , Mehta, Anurag
    The breast journal v.24 no.4 ,pp. 468 - 472 , 2018 , 1075-122x ,

    초록

    Abstract The ASCO/CAP guidelines for HER2 reporting in breast cancer published in 2007 and were updated in 2013 to assure that the right patient receives the targeted therapy. The updated guidelines have lowered the threshold for HER2 positivity criteria and altered the equivocal category for both IHC and FISH. This first study from India addresses the impact of these updated guidelines in the various reporting categories at a tertiary care centre. We compared the trend of HER2 IHC reporting 1 year before (Period A) and 1 year after (Period B) the implementation of updated 2013 ASCO/CAP guidelines. All HER2 equivocal IHC cases of post 2013 guidelines were reclassified as per 2007 guidelines to detect additional number of cases that have been put into equivocal category. Reflex FISH correlation was also assessed to detect any additional cases eligible for anti HER2 therapy with implementation of these updated guidelines. With implementation of updated 2013 guidelines, there was significant decrease in the number of cases scored as 1+ (from 30.7% to 20.6%; P value: .0001) while significant increase in number of 2+ cases (from 20.2% to 27.3%; P value: .004). Post 2013 guidelines, 39% (64 cases) of tumors were additionally put into the equivocal category which would have been considered as negative (score 1+) as per 2007 guidelines. The reflex FISH testing in these equivocal cases resulted in detection of only 1.5% of additional cases eligible for anti HER2 therapy. With implementation of updated 2013 guidelines, there is no significant increase in HER2 positivity trend. However, there is appreciable increase in IHC equivocal cases which subsequently led to increased reflex FISH testing without significantly contributing to the detection of additional eligible cases for anti HER2 therapy, but resulted in delaying of definite HER2 status along with financial implications.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  5. [해외논문]   Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long‐term results from a single institution experience   SCIE

    Martin‐ (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spain) , Romano, Patricia (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spain) , Baraibar, Iosune (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spain) , Espinó (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spain) , s, Jaime (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spain) , Legaspi, Jairo (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spain) , Ló (Department of Medical Oncology. Clínica, Universidad de Navarra, Pamplona, Navarra, Spain) , pez‐ (Department of Medical Oncology. Clí) , Picazo, Jose M. , Aramendí , a, Jose Manuel , Ferná , ndez, Oscar A. , Santisteban, Marta
    The breast journal v.24 no.4 ,pp. 473 - 479 , 2018 , 1075-122x ,

    초록

    Abstract The combination of Pegylated Liposomal Doxorubicin (PLD) plus Gemcitabine (GEM) has been previously investigated in the treatment of metastatic breast cancer (MBC). PLD is a doxorubicin formulation with prolonged circulation time and better tissue distribution. GEM is a nucleoside analog with nonoverlapping toxicity compared to PLD. The aim of our study was to assess efficacy, toxicity, and long‐term outcome of this combination. Patients with heavily treated MBC were retrospectively analyzed. Chemotherapy consisted of PLD 25 mg/m 2 and GEM 800 mg/m 2 day 1, on a three‐week schedule. Cardiac function was evaluated baseline and during treatment. Radiological response was graded according to RECIST criteria v1.1. Toxicity was scored according to CTCAE v4.0. Progression‐free survival (PFS) and overall survival (OS) were evaluated. From 2001 to 2014, 122 pts were included. Median age was 55 (range: 28‐84). Median previous treatment schedules in the metastatic scenario were 3 (range: 1‐15). Most patients received prior anthracyclines (85%). Median number of metastatic sites was 2 (range: 1‐7). Median number of cycles delivered was 5 (range: 1‐36). Overall response rate was 31% (5% complete responses; 26% partial responses). Stable and progressive diseases were observed in 32% and 26% of patients. Grade ≥3 neutropenia was observed in 29 patients (24%). Grade ≥3 hand‐foot syndrome was detected in 17 patients (14%), mostly since cycle 3 (88%). Median cumulative PLD dose was 125 mg/m 2 . At a median follow‐up of 101 months, median PFS and OS were 7 and 22 months, respectively. PLD‐GEM combination achieves remarkable long‐term outcomes with an acceptable toxicity profile in patients with MBC.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  6. [해외논문]   Is extracapsular nodal extension in sentinel nodes a predictor for nonsentinel metastasis and is there an impact on survival parameters?—A retrospective single center cohort study with 324 patients   SCIE

    Schwentner, Lukas (Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany) , Dayan, Davut (Department of Gynecology and Obstetrics, Kliniken Landkreis Heidenheim gGmbH, Heidenheim, Germany) , Wö (Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany) , ckel, Achim (Department of Gynecology and Obstetrics, Kliniken Landkreis Heidenheim gGmbH, Heidenheim, Germany) , Janni, Wolfgang (Department of Gynecology and Obstetrics, Kliniken Landkreis Heidenheim gGmbH, Heidenheim, Germany) , Kreienberg, Rolf (Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz, Germany) , Blettner, Maria (Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz, Germany) , Wollschlä , ger, Daniel
    The breast journal v.24 no.4 ,pp. 480 - 486 , 2018 , 1075-122x ,

    초록

    Abstract The Z0011 trial has fundamentally changed axillary management in breast cancer patients. However, some important questions remain, like the role of extracapsular nodal extension (ENE) in positive sentinel nodes and the need for further axillary treatment. In this retrospective cohort study, we reviewed and analyzed data from 342 clinically node negative (cN0) breast cancer patients with a positive sentinel node and subsequent axillary lymph node dissection (ALND) from the BRENDA data base. The 104 (30.4%) ENE positive patients had a significantly higher proportion of ≥3 positive axillary lymph nodes (65.0%) compared to ENE negative patients with a positive sentinel node (21.4%). Likewise, ENE positive patients had significantly more often lymph node metastasis size >2 mm (96.2%) than ENE negative patients (72.7%). T1 status was observed significantly more often in ENE negative patients (53.2%) than in ENE positive patients (24.0%). While ENE was linked to worse overall survival in univariate analysis, this effect disappeared when adjusting for nodal status, age, and comorbidities in multivariate analysis. ENE of the sentinel node is an important predictor for nonsentinel lymph node involvement. We suggest that ENE influences survival only via a higher number of positive nodes – one of the most predictive parameters for survival outcome in breast cancer.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  7. [해외논문]   Distinguishing papillary endothelial hyperplasia and angiosarcoma on core needle biopsy of the breast: The importance of clinical and radiologic correlation   SCIE

    Guilbert, Marie‐ (Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA) , Christine (Harvard Medical School, Boston, MA, USA) , Frost, Elisabeth P. (Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA) , Brock, Jane E. (Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA) , Lester, Susan C.
    The breast journal v.24 no.4 ,pp. 487 - 492 , 2018 , 1075-122x ,

    초록

    Abstract Papillary endothelial hyperplasia (PEH) is a rare non‐neoplastic exuberant organizing hematoma that can closely mimic angiosarcoma due to a resemblance to malignant anastomosing blood vessels. It could be particularly difficult to distinguish PEH from angiosarcoma in breast core needle biopsies. We identified all cases of these lesions diagnosed on core needle biopsy in order to identify clinical, radiologic, and pathologic features that could prove helpful to arrive at the correct diagnosis. Four cases of PEH and 4 cases of angiosarcoma were identified. The mean age at diagnosis was 62 for PEH and 33 for primary angiosarcoma. All cases of PEH formed small masses with circumscribed or lobulated margins by imaging (mean size 0.9 cm). In 3 cases, the masses were difficult or impossible to identify after the biopsy. Angiosarcomas presented as larger masses with ill‐defined margins (mean size 2.8 cm) that were unchanged in size after biopsy. PEH was surrounded by adipose tissue, whereas angiosarcoma invaded into fibrous stroma and involved lobules. The pseudopapillary structures of PEH were composed mainly of collagen, and thus, additional histologic stains for fibrin were not helpful for diagnosis. The 4 patients with PEH received no further treatment and are alive and disease‐free at 2‐11 years of follow‐up. In contrast, the patients with angiosarcoma underwent mastectomy and chemotherapy or radiation therapy. Two of the patients with angiosarcoma died 3 years after diagnosis and the other 2 patients are alive without disease at 5 and 6 years. Therefore, distinguishing PEH and angiosarcoma is essential for appropriate management. This is the first series to compare these lesions on core needle biopsy and the first to note important clinical, imaging, and histologic differences that aid in making a diagnosis of PEH with confidence on breast core needle biopsy.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  8. [해외논문]   The case for the omission of axillary staging in invasive breast carcinoma that exhibits a predominant tubular growth pattern on preoperative biopsy   SCIE

    Ramzi, Saed (Primrose Beast Care Centre, Derriford Hospital, Plymouth, UK) , Hyett, Elaine L. (Primrose Beast Care Centre, Derriford Hospital, Plymouth, UK) , Wheal, Abigail S. (Department of Cellular & Anatomical Pathology, Derriford Hospital, Plymouth, UK) , Cant, Peter J. (Primrose Beast Care Centre, Derriford Hospital, Plymouth, UK)
    The breast journal v.24 no.4 ,pp. 493 - 500 , 2018 , 1075-122x ,

    초록

    Abstract True invasive tubular breast carcinoma (TBC) is unlikely to metastasize to axillary nodes, yet it is routinely subjected to sentinel lymph node biopsy (SLNB), even if the diagnosis was suspected preoperatively. The positive predictive value (PPV) of core biopsy for TBC and the incidence and predictors of axillary metastasis in invasive breast carcinomas identified as tubular‐rich on core biopsy are unknown. Prospective patient and tumor data regarding postoperatively confirmed TBCs, and tubular‐rich carcinoma identified on preoperative core biopsy between January 2005 and May 2016 was analyzed retrospectively. Axillary metastasis occurred in only 4.2% (4/95) of TBCs, all of which measured >15 mm pathologically. In 11.1% (11/99) of TBCs, the initial core biopsy was either indeterminate/suspicious or ductal carcinoma in situ (DCIS); therefore, their true tubular histotype and size were ascertained following operative excision and before SLNB. Nine were ≤15 mm, and all were node‐negative. Only 63.9% (46/72) of tubular‐rich core biopsies were confirmed as TBCs; the remaining 36.1% (26/72) were well‐differentiated invasive nontubular carcinomas. None of the preoperative patient or tumor features were predictive of true TBC on multivariable analysis; 10.1% (7/69) of carcinomas identified as tubular‐rich on core biopsy (regardless of their true histotypes) were node‐positive; 23.1% (6/26) in nontubular and 2.3% (1/43) in true tubular carcinomas. Preoperative ultrasound size >15 mm was associated with axillary metastasis in 40.0% (4/10) compared to 5.7% (3/53) in those ≤15 mm (OR = 11.11, 95% CI = 1.99‐62.04; multivariable P = .010). Axillary metastasis in TBC is dependent on pathological size; therefore, a case is made for omitting SLNB in small true TBCs confirmed following excision. Preoperative tubular‐rich core biopsy is not adequately diagnostic of TBC; however, it selects carcinomas that are well‐differentiated, small, and unlikely to metastasize to the axilla, thus allowing for the selective omission of SLNB.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  9. [해외논문]   Eligibility of patients for minimally invasive breast cancer therapy based on MRI analysis of tumor proximity to skin and pectoral muscle   SCIE

    Merckel, Laura G. (Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands) , Verburg, Erik (Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands) , van der Velden, Bas H.M. (Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands) , Loo, Claudette E. (Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands) , van den Bosch, Maurice A.A.J. (Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands) , Gilhuijs, Kenneth G.A. (Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands)
    The breast journal v.24 no.4 ,pp. 501 - 508 , 2018 , 1075-122x ,

    초록

    Abstract There is growing interest in minimally invasive breast cancer therapy. Eligibility of patients is, however, dependent on several factors related to the tumor and treatment technology. The aim of this study is to assess the proportion of patients eligible for minimally invasive breast cancer therapy for different safety and treatment margins based on breast tumor location. Patients with invasive ductal cancer were selected from the MARGINS cohort. Semiautomatic segmentation of tumor, skin, and pectoral muscle was performed in Magnetic Resonance images. Shortest distances of tumors to critical organs (ie, skin and pectoral muscle) were calculated. Proportions of eligible patients were determined for different safety and treatment margins. Three‐hundred‐forty‐eight patients with 351 tumors were included. If a 10 mm safety margin to skin and pectoral muscle is required without treatment margin, 72.3% of patients would be eligible for minimally invasive treatment. This proportion decreases to 45.9% for an additional treatment margin of 5 mm. Shortest distances between tumors and critical organs are larger in older patients and in patients with less aggressive tumor subtypes. If a 10 mm safety margin to skin and pectoral muscle is required, more than two‐thirds of patients would be eligible for minimally invasive breast cancer therapy.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  10. [해외논문]   Clinical and histologic characteristics of breast cancers in women with previous pathologic diagnosis of benign breast disease in Spain   SCIE

    Romá (Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain) , n, Marta (Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain) , Caicoya, Martin (Department of Health, Catalan Cancer Plan, Barcelona, Spain) , Espinà (Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain) , s, Josep (Preventive Medicine and Epidemiology Department, Hospital Clinic, Barcelona, Spain) , Sala, Maria (Epidemiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain) , Torá (Department of Obstetrics and Gynecology, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain) , ‐ (Breast Cancer Screening Program of Tarragona, The F) , Rocamora, Isabel , Quinta, Maria J. , Vernet, Mar , Saladié , , Francina , Romero, Anabel , Sá , nchez, Mar , Baré , , Marisa , Vidal, Carmen , Servitja, S. , Natal, Carmen , Corominas, Joosep , Ferrer, Joana , Rodrí , guez‐ , Arana, Ana , Castells, Xavier , Buró , n, Andrea , Andreu, Xavier , Aracil, Llucia Benito , Quintana, Marí , a Jesú , s , Posso, Margarita , Solà , ‐ , Roca, Judit , Galceran, Jaume
    The breast journal v.24 no.4 ,pp. 509 - 518 , 2018 , 1075-122x ,

    초록

    Abstract Women with a benign breast disease (BBD) have an increased risk of subsequent breast carcinoma. Information is scarce regarding the characteristics of breast carcinomas diagnosed after a BBD. Our aim was to point out the differences in clinical and histologic characteristics of breast carcinomas diagnosed in women with and without a previous pathologic diagnosis of BBD in the context of population‐based mammography screening. Retrospective cohort study of all women aged 50‐69 years who were screened at least once in a population‐based screening program in Spain, between 1994 and 2011 and followed up until December 2012. The mean follow‐up was 6.1 years. We analyzed 6645 breast carcinomas, of whom 238 had a previous pathologic diagnosis of BBD. Information on clinical and histologic characteristics was collected from pathology reports. Logistic regression was used to estimate the odds ratio (OR) and 95% confidence intervals (95%CI) of occurrence of selected histologic characteristics of breast carcinomas in women with and without a previous BBD. Women with a previous BBD had a higher proportion of ductal carcinoma in situ (DCIS) compared with women without a BBD (22.1% and 13.6%, respectively). Among those diagnosed with an invasive breast carcinoma, women with previous BBD were more likely to be diagnosed with carcinomas sized >2 cm (OR = 1.46; 95%CI = 1.03‐2.08), metastatic positive (OR = 2.66; 95%CI = 1.21‐5.86), and with a high Ki‐67 proliferation rate (OR = 1.93; 95%CI = 1.24‐2.99). No differences were found across histologic subtypes of BBD. Screening participants with a previous pathologic diagnosis of BBD had a higher proportion of DCIS. However, invasive carcinomas detected in women with a BBD were associated with clinical and histologic characteristics conferring a worst prognosis.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지

논문관련 이미지